| Literature DB >> 28823556 |
Erica Korb1, Margaret Herre2, Ilana Zucker-Scharff2, Jodi Gresack3, C David Allis4, Robert B Darnell5.
Abstract
Fragile X syndrome (FXS) is a leading genetic cause of intellectual disability and autism. FXS results from the loss of function of fragile X mental retardation protein (FMRP), which represses translation of target transcripts. Most of the well-characterized target transcripts of FMRP are synaptic proteins, yet targeting these proteins has not provided effective treatments. We examined a group of FMRP targets that encode transcriptional regulators, particularly chromatin-associated proteins. Loss of FMRP in mice results in widespread changes in chromatin regulation and aberrant gene expression. To determine if targeting epigenetic factors could reverse phenotypes associated with the disorder, we focused on Brd4, a BET protein and chromatin reader targeted by FMRP. Inhibition of Brd4 function alleviated many of the phenotypes associated with FXS. We conclude that loss of FMRP results in significant epigenetic misregulation and that targeting transcription via epigenetic regulators like Brd4 may provide new treatments for FXS.Entities:
Keywords: Brd4; FMRP; FXS; chromatin; histones
Mesh:
Substances:
Year: 2017 PMID: 28823556 PMCID: PMC5740873 DOI: 10.1016/j.cell.2017.07.033
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582